LA JOLLA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat serious autoimmune and inflammatory disorders, today announced that
Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of $20 million in
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind, placebo-controlled study will
LA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new
LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that
LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it will host a
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer to lead clinical
LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1,
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that
LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new
